BridgeBio Pharma, Inc. (BBIO) Operating margin 2019–2025
BridgeBio Pharma, Inc. (BBIO) operating margin by fiscal year — reported operating income divided by reported revenue.
-104.2%FY2025 · since FY2019: -656.4% → -104.2%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -104.2% | +163.0 pp |
| FY2024 | -267.2% | +6261.5 pp |
| FY2023 | -6528.8% | -5869.1 pp |
| FY2022 | -659.6% | +167.5 pp |
| FY2021 | -827.1% | +4924.9 pp |
| FY2020 | -5752.0% | -5095.6 pp |
| FY2019 | -656.4% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice